A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms PASSOS
- Sponsors Novartis Pharmaceuticals
- 26 Oct 2016 Planned End Date changed from 1 Jun 2018 to 1 Jan 2019.
- 26 Oct 2016 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.
- 26 Oct 2016 Status changed from recruiting to active, no longer recruiting.